Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?
ConclusionsContralateral parenchymal enhancement on dynamic contrast-enhanced MRI was not associated with tumor-derived estrogen receptor pathway activity.
Source: European Journal of Radiology - Category: Radiology Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Cancer | Cancer & Oncology | Endocrine Therapy | Genetics | HER2 | MRI Scan | Perfusion | Radiology